Blood Screening Market
Buy Now Request Sample Explore
Home › Report Store › Life Sciences  › Blood Screening Market

Blood Screening Market Outlook: Size, Share, Trends, Growth Analysis, Competitive Landscape & Forecast, 2026-2033

The Blood Screening Market size was valued at US$ 3.83 Billion in 2025 and is projected to reach US$ 8.49 Billion by 2033, growing at a CAGR of 10.46% during 2026–2033, supported by rising transfusion safety requirements, expanding blood donation programs, molecular testing adoption, and laboratory automation.

Report Coverage
  • Product Type: Instruments, Reagents & Kits
  • Technology: Molecular Tests, Serology Tests
  • End User: Independent Clinical Laboratories, Hospital-based Laboratories, Others
US$ 3.83 Bn Market size in 2025
US$ 8.49 Bn Market Size by 2033
10.46% CAGR, 2026 - 2033
2026-2033 Forecast Period
01 AI Overview

Blood Screening Market Summary

  • North America Region: North America holds a 35%–38% share in 2025, growing at a 9.6%–10.0% CAGR during 2026–2033, supported by established blood banking networks, sophisticated laboratories, automation, molecular diagnostics, and stringent quality controls. The U.S. represents the largest regional market, with a 9.8%–10.2% CAGR through 2033, supported by high testing volumes and advanced laboratory infrastructure.
  • Fastest Growing Region: Asia Pacific accounts for a 23%–26% share in 2025, expanding at a 12.0%–12.5% CAGR during 2026–2033, driven by expanding transfusion infrastructure, rising diagnostic capacity, blood safety initiatives, laboratory modernization, and broader adoption of automated screening technologies across developing healthcare systems.
  • Leading Segment: Reagents & Kits hold a 58%–61% share in 2025, advancing at a 10.7%–11.1% CAGR during 2026–2033, supported by recurring testing requirements, growing molecular and serological screening volumes, assay menu expansion, workflow standardization, and increased demand for reliable high-throughput screening.
  • High Growth Segment: Molecular Tests account for a 42%–45% share in 2025, registering a 12.2%–12.7% CAGR during 2026–2033, as laboratories prioritize sensitive pathogen detection, shorter diagnostic windows, multiplex testing, automation compatibility, and improved screening accuracy for donated blood.
  • Key Market Opportunity: Expansion of automated molecular screening, centralized laboratory networks, emerging-market blood banks, multiplex assays, and integrated workflows creates opportunities for diagnostic suppliers to improve throughput while reducing manual processing and operational variability.
  • Major Market Players: Bio-Rad Laboratories, Inc., Grifols, S.A., F. Hoffmann-La Roche Ltd., Ortho Clinical Diagnostics, Becton, Dickinson and Company, DiaSorin S.p.A., Thermo Fisher Scientific Inc., Abbott Laboratories, and Quotient Limited.
02 Strategic Insights

Blood Screening Market: Strategic Insights

Blood Screening Market Strategic Framework
FREE PDF
Request your free sample
Request free sample
03 Stakeholder View

Key Takeaways

  • The value chain is increasingly integrating diagnostic companies, reagent suppliers, instrument providers, blood banks, independent laboratories, hospitals, distributors, and quality control firms. Integration in such an ecosystem is essential to ensure proper workflow process, availability of reagents, reliability of instruments, and traceability.
  • Reagents & Kits offer an attractive subscription business model given that the testing process requires continuous use regardless of the number of donors. Molecular tests offer further value given the need for higher sensitivity and multiplex testing capability.
  • Trends in product development include moving towards automation-friendly assays, integrated analyzers, workflow solutions, increased throughput, and laboratory management through software. Companies that are able to integrate consumables with instruments and workflow solutions would be able to improve their ability to retain customers.
  • Asia Pacific provides an interesting region to enter due to the fact that the development of the infrastructure for blood banking leads to an increased need for scalable testing platforms. Suppliers will be able to address regions where the number of tests exceeds the capabilities of current laboratories.
  • Competitive advantage is increasingly being defined by the range of assays, instrument integration, reagent reliability, service networks, and high-volume laboratory capability.
04 Geographic Outlook

Blood Screening Market Regional Highlights

North America Blood Screening Market

North America holds a 35%–38% share in 2025 and is projected to expand at a 9.6%–10.0% CAGR during 2026–2033. The region benefits from mature blood banking infrastructure, advanced laboratories, automation, and established quality-management practices. The Blood Screening Market share is supported by replacement demand for sophisticated instruments and continued adoption of integrated testing workflows. The United States remains the principal regional contributor, supported by extensive transfusion services and advanced diagnostic capabilities.

  • Mature laboratory networks continue replacing manual procedures with automated systems capable of standardized, high-volume donor screening and improved workflow consistency.
  • Molecular testing adoption supports demand for sensitive assays, while established blood centers provide a stable customer base for recurring reagent and kit consumption.
  • Instrument suppliers increasingly compete through throughput, assay breadth, connectivity, maintenance capabilities, and integrated workflow solutions rather than standalone analytical performance.
  • Regulatory quality expectations encourage laboratories to maintain robust validation, documentation, quality control, and traceability practices across donor screening workflows.

US Blood Screening Market

The U.S. accounts for approximately 25%–28% of global revenue in 2025, representing a substantial portion of North American demand, with a 9.8%–10.2% CAGR during 2026–2033. Large blood collection organizations, hospital laboratories, independent diagnostic facilities, and established testing networks support recurring screening volumes. The U.S. market also benefits from broad availability of automated molecular and serological platforms.

  • High laboratory sophistication supports adoption of integrated analyzers that combine automated sample handling, assay processing, quality controls, and result management.
  • Large-scale blood screening operations favor platforms capable of maintaining consistent throughput while limiting manual intervention and reducing workflow variability.
  • Established procurement structures encourage suppliers to differentiate through service coverage, reagent availability, equipment reliability, and comprehensive technical support.

Europe Blood Screening Market

Europe represents a 27%–30% share in 2025, expanding at a 9.0%–9.4% CAGR during 2026–2033. Germany, France, the United Kingdom, and Italy remain important markets because of established transfusion infrastructure. Higher-growth opportunities are developing across Central and Eastern Europe as laboratories modernize testing capacity. The Blood Screening Market growth across Europe is therefore linked to automation, standardized workflows, laboratory consolidation, and increasing emphasis on operational efficiency.

  • Germany maintains a strong position through sophisticated diagnostic infrastructure, established blood services, and demand for automated laboratory technologies supporting high-volume screening.
  • France and the United Kingdom continue emphasizing standardized testing workflows, quality management, and efficient blood-service operations, supporting recurring demand for screening consumables.
  • Italy provides opportunities for modernization as laboratories seek improved automation, higher throughput, and dependable screening platforms capable of supporting evolving testing requirements.
  • Central and Eastern European markets offer faster expansion potential as laboratory infrastructure develops and healthcare systems increase investment in advanced diagnostic capabilities.

Asia Pacific Blood Screening Market

Asia Pacific accounts for a 23%–26% share in 2025 and is forecast to expand at a 12.0%–12.5% CAGR during 2026–2033, making it the fastest-growing region. Rising healthcare investment, expanding blood collection systems, laboratory modernization, and increasing testing capacity are supporting adoption. China, Japan, South Korea, and India represent major opportunities, while Southeast Asian markets provide additional expansion potential. The regional Blood Screening Market share is expected to strengthen as laboratories transition toward automated and molecular screening platforms.

  • China combines substantial healthcare infrastructure with expanding laboratory capacity, creating opportunities for high-throughput screening systems, molecular assays, and locally supported diagnostic workflows.
  • India offers significant long-term potential as blood banking infrastructure expands and laboratories seek scalable screening technologies capable of supporting increasing testing requirements.
  • Japan and South Korea provide mature technology markets where automation, analytical performance, workflow integration, and laboratory productivity influence purchasing decisions.
  • Southeast Asian countries provide emerging opportunities as healthcare modernization increases demand for standardized testing systems and dependable access to screening reagents.

Rest of World Blood Screening Market

Rest of World represents approximately 9%–12% market share in 2025 and is projected to expand at a CAGR of 10.7%–11.5% through 2033. Growth across South and Central America is supported by increasing healthcare investments, broader infectious disease monitoring initiatives, and modernization of blood bank infrastructure. Brazil and Mexico remain the leading contributors, benefiting from expanding diagnostic laboratory capacity.

  • Brazil provides a substantial addressable market because of its healthcare scale, organized blood services, and increasing laboratory modernization requirements.
  • Mexico offers opportunities for suppliers capable of providing scalable screening platforms, dependable consumables, and technical support across centralized and regional testing facilities.
  • Gulf markets continue developing advanced healthcare infrastructure, creating demand for sophisticated laboratory systems and standardized screening technologies.
  • Selected African markets provide longer-term potential as blood collection networks, diagnostic infrastructure, and transfusion safety capabilities improve.
Global Market Geography
FREE PDF
Request your free sample
Request free sample
05 Segment Analysis

Blood Screening Market Segmentation

Product Type

Product Type represents a core purchasing dimension because laboratories require both instruments and recurring consumables to complete donor screening workflows. Reagents & Kits command a 58%–61% share in 2025 and are projected to expand at a 10.7%–11.1% CAGR during 2026–2033. The Blood Screening Market scope is strengthened by recurring assay consumption, broader testing menus, automation compatibility, and increasing laboratory throughput requirements.

  • Instruments: Automated analyzers support standardized sample processing, higher throughput, and reduced manual handling. Replacement cycles, workflow automation, and demand for integrated laboratory platforms sustain equipment investment.
  • Reagents & Kits: Recurring assay consumption makes this category central to laboratory operations. Expanding screening volumes, broader pathogen panels, molecular workflows, and standardized testing protocols support continued demand.

Technology

Technology segmentation reflects the shift from conventional screening toward more sensitive and workflow-efficient diagnostic approaches. Molecular Tests hold a 42%–45% share in 2025 and are projected to register a 12.2%–12.7% CAGR during 2026–2033. These platforms increasingly influence Blood Screening Market trends through higher analytical sensitivity, multiplex capabilities, automation compatibility, and demand for efficient pathogen detection.

  • Molecular Tests: Molecular platforms enable sensitive pathogen detection and support shorter detection windows. Automation, multiplex capabilities, and increasing laboratory sophistication encourage adoption across high-volume blood screening environments.
  • Serology Tests: Serological methods remain essential for established screening workflows and broad testing requirements. Their established laboratory presence, assay familiarity, and compatibility with routine platforms maintain sustained utilization.

End User

End-user demand is shaped by blood collection volumes, laboratory capacity, regulatory obligations, and testing complexity. Hospital-based laboratories account for an estimated 41%–44% share in 2025 and are projected to expand at 10.2%–11.0% CAGR. Rising transfusion procedures, healthcare infrastructure investments, and the need for integrated diagnostic services continue strengthening adoption across clinical settings.

  • Independent Clinical Laboratories: These facilities emphasize throughput, assay reliability, operational efficiency, and equipment utilization. Automated workflows can help laboratories manage growing sample volumes while maintaining consistent screening processes.
  • Hospital-based Laboratories: Hospital laboratories require dependable screening capabilities integrated into broader diagnostic workflows. Demand is supported by transfusion services, emergency testing requirements, laboratory automation, and continuous access to reagents.
06 Market Forces

Blood Screening Market Dynamics

Key Market Drivers

Rising Demand for Safe Blood Supplies

The growing emphasis on transfusion safety is increasing the need for dependable screening systems across blood banks, hospitals, and independent laboratories. Higher testing requirements are encouraging laboratories to adopt technologies that provide consistent analytical performance while handling increasing sample volumes. Molecular and serological testing platforms are increasingly important because screening accuracy directly influences the safety of donated blood and blood components. The Blood Screening Market growth is therefore being supported by continued investment in automated instruments, reagents, quality-control systems, and integrated laboratory workflows. These requirements are shaping market trends toward higher-throughput platforms, standardized testing processes, and technologies capable of supporting reliable screening across centralized and regional blood-testing facilities.

Growing Blood Donation Activities

Expansion of the blood donation process has increased the number of samples that need to be systematically tested prior to their use through the transfusion system. The organization of blood collection processes has meant that blood banks need testing systems that can process high volumes without causing bottlenecks in the lab work process. The increase in the donations process has also ensured a constant demand for consumables, since each and every tested sample needs its own testing kits. Laboratories have thus been considering testing technologies in relation to their throughput, reagent efficiency, workflow and systems compatibility.

Increasing Focus on Transfusion Safety

Greater attention to transfusion safety is encouraging healthcare organizations to strengthen screening protocols, quality management, and laboratory traceability. Blood centers and hospitals demand devices that will provide accurate results while keeping the process standardized despite the high volume of tests performed. In response to this, diagnostic companies have been developing more instrument integration, improved assay performance, better sample handling, and automated workflows. The emphasis has shifted from the performance of individual tests to the effectiveness and accuracy of the screening process as a whole. This means the Blood Screening Market trends has been shaped increasingly by investments made in consistency, error reduction, and proper laboratory documentation. This is also promoting a move towards an integrated screening environment where all parts work together.

Key Market Opportunities

Expanding Blood Bank Infrastructure

Expansion and modernization of blood bank infrastructure is creating opportunities for suppliers of screening instruments, reagents, molecular assays, and laboratory automation systems. Facilities that are new and have been modernized need technologies that will be able to handle more donors at a time while providing uniform testing methods. Centralized blood testing facilities are ideal for high-throughput technology because large sample numbers will increase efficiency and help achieve uniformity in the lab process. Suppliers will be able to consolidate their position in the market by integrating their equipment with other services such as training and service agreements. As the infrastructure of the blood banks grows in developing healthcare systems, flexible platforms become an asset to vendors.

Increasing Screening in Emerging Healthcare Markets

Emerging healthcare markets provide significant opportunities as governments, healthcare organizations, and diagnostic providers expand blood collection and testing infrastructure. Cost continues to be an important factor in making purchases; however, laboratories have begun assessing their technologies based on their throughput capacity, reliability, maintenance needs, and total costs of operations. Partnerships with hospitals, blood banks, distributors, and diagnostics networks would help to provide better access to screening technologies. With the development of healthcare infrastructure, the growing demand is expected to be towards automation and molecular testing. The Blood Screening Market Forecast is influenced not only by growth in health care expenditure but also by the rate of development of healthcare systems.

Growing Demand for Rapid Testing Solutions

The increasing demand for more efficient screening procedures presents a potential market for technologies capable of increasing efficiency while retaining the reliability of analysis. Blood centers with high throughput require systems capable of reducing the manual steps involved, automating repetitive laboratory procedures, and rapidly processing of samples. The molecular diagnostic platforms are best suited for this need since they offer sensitive analysis along with automated laboratory process. Rapid diagnostics are equally important for laboratories with labor constraints and increasing test loads.

Market Restraints and Challenges

High Screening Costs

Factor: Advanced screening technologies, including nucleic acid testing systems, automated analyzers, and specialized reagents, require substantial capital and operational expenditures. Impact: Implementation and maintenance costs can act as barriers for use in smaller laboratories, regional blood banks, and hospitals that have restricted finances. Purchasing considerations include having to consider regulations and available finances, especially in new markets. Even though better technology enhances the safety and effectiveness of diagnostics, cost issues may pose a barrier to modernization efforts.

Stringent Regulatory Requirements

Factor: Blood screening products are subject to rigorous validation, approval, quality-control, and post-market surveillance requirements across major healthcare markets. Impact: Regulatory complexity can increase development timelines, elevate compliance costs, and delay product commercialization. Manufacturers frequently need to conduct extensive performance studies and documentation processes before product approval. Differences in regulatory frameworks between countries may require additional localization efforts and resource commitments. Continuous updates to safety standards also necessitate ongoing investment in product enhancements and compliance management.

07 Company Analysis

Competitive Landscape

The Blood Screening Market analysis indicates a competitive environment shaped by diagnostic technology breadth, assay portfolios, instrument capabilities, laboratory automation, service infrastructure, and recurring consumable relationships. Major participants compete across molecular and serological testing, while integrated product portfolios can strengthen customer retention.

Company Name

Overview

Products and Services relevant to this market

Bio-Rad Laboratories, Inc.

A major diagnostics and life sciences company with established laboratory testing capabilities and broad diagnostic expertise.

Blood screening reagents, diagnostic systems, quality-control products, immunohematology solutions, and laboratory testing technologies.

Grifols, S.A.

A healthcare company with extensive involvement in plasma, transfusion medicine, diagnostics, and blood-management activities.

Blood screening technologies, diagnostic systems, transfusion-related testing solutions, reagents, and laboratory products.

F. Hoffmann-La Roche Ltd.

A global healthcare company with extensive molecular diagnostics and laboratory automation capabilities.

Molecular diagnostic systems, infectious-disease assays, automated analyzers, reagents, and integrated laboratory workflows.

Ortho Clinical Diagnostics

A diagnostics provider focused on laboratory testing, immunohematology, and transfusion-related diagnostic applications.

Blood typing and screening systems, immunohematology reagents, analyzers, and transfusion medicine solutions.

Becton, Dickinson and Company

A diversified medical technology company with substantial diagnostic and laboratory technology capabilities.

Diagnostic instruments, molecular testing technologies, laboratory automation, sample-management solutions, and testing consumables.

DiaSorin S.p.A.

A diagnostics specialist with established expertise in immunodiagnostics and molecular diagnostic technologies.

Immunoassays, molecular diagnostic tests, automated platforms, reagents, and infectious-disease testing solutions.

Thermo Fisher Scientific Inc.

A broad life sciences and diagnostics supplier serving laboratories across research and clinical environments.

Molecular testing platforms, reagents, sample preparation technologies, laboratory instruments, and workflow solutions.

Abbott Laboratories

A diversified healthcare company with extensive diagnostics capabilities and established laboratory customer relationships.

Molecular diagnostics, serology testing, automated analyzers, reagents, infectious-disease assays, and laboratory systems.

Quotient Limited

A diagnostics company focused on transfusion medicine and automated blood testing technologies.

Blood grouping, antibody screening, compatibility testing, automated immunohematology systems, and associated consumables.
     
10 Trust & Transparency

Research Methodology

The market analysis combines proprietary research with secondary data from government agencies, company disclosures, regulatory filings, industry databases and expert interviews. Market estimates are validated through data triangulation, cross-market benchmarking and analyst review.

View Full Research Methodology
11 Questions Answered

Frequently Asked Questions

What does the Blood Screening Market Report indicate about future competition?

The market report suggests that competition will increasingly focus on automation, molecular diagnostics, workflow integration, assay accuracy, and strategic partnerships targeting transfusion safety improvements and laboratory modernization.

What factors make Asia Pacific an attractive investment destination?

Rapid healthcare infrastructure development, laboratory modernization, increasing blood donation programs, expanding infectious disease surveillance, and government support for diagnostic upgrades are creating substantial growth opportunities.

Why are reagents and kits generating the largest revenue contribution?

Reagents and kits are consumed during every screening procedure, creating recurring demand. Increasing testing volumes, regulatory requirements, and routine donor screening activities support their dominant revenue position.

Which technology segment is expected to experience the fastest expansion?

Molecular testing is projected to experience the strongest growth due to its ability to identify pathogens earlier, reduce detection window periods, and deliver greater analytical sensitivity compared with conventional methods.

What are the primary applications of blood screening technologies?

Blood screening technologies are primarily used to detect transfusion-transmissible infections, verify donor eligibility, support blood banking operations, improve patient safety, and ensure regulatory compliance before blood transfusions occur.

Access the Full Blood Screening Market Report

Get segment-level forecasts, regional estimates, competitive benchmarking, company profiles and downloadable Excel datasets.

Download Sample Request Customization
Access the full Blood Screening Market Report
350 pages PDF & Excel | 2026-08-19
Download Sample Customization